CAMBRIDGE, Mass.--(EON: Enhanced Online News)--Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics for ocular diseases, announced today that Eric Furfine, Ph.D., Eleven’s Chief Scientific Officer, is scheduled to present at the Targeting Ocular Disorders Conference being held September 26-27, 2013 in Boston, MA. The presentation, entitled ‘Inhibition of Cytokine Signaling to Treat Ocular Diseases,’ will take place on Friday, September 27, 2013 at 2:20 p.m. ET during the Looking to the Future session which Dr. Furfine will also chair. Dr. Furfine will discuss new approaches to cytokine signaling blockade for the treatment of ocular disease, highlighting examples from Eleven Biotherapeutic’s proprietary product pipeline, including interleukin-17 blockade for the potential treatment of uveitis and age-related macular degeneration, interleukin-6 blockade for the potential treatment of diabetic macular edema and interleukin-1 blockade with EBI-005 for the treatment of dry eye disease.
Eleven Biotherapeutics’ lead product candidate, EBI-005, is a novel, interleukin-1 (IL-1) receptor antagonist currently entering pivotal clinical development as a rationally-designed topical protein for the treatment of inflammatory diseases at the surface of the eye. Clinical studies in patients with dry eye disease, conducted by both Eleven and collaborators, have validated the blockade of IL-1 as an efficacious mechanism for treating dry eye disease. Eleven’s first clinical study of EBI-005 in patients with dry eye disease demonstrated that EBI-005 was generally safe, well-tolerated, and showed statistically significant improvements in signs and symptoms of dry eye disease when compared to baseline. EBI-005 has been designed to have optimal physical, pharmaceutical and therapeutic properties, including topical ophthalmic administration, for the treatment of ocular diseases including dry eye and severe ocular allergy.
About Eleven Biotherapeutics
Eleven Biotherapeutics creates novel and differentiated biotherapeutics that are first-of-a-kind protein-based drugs with significantly improved physical and pharmaceutical characteristics designed to provide therapeutic benefits. The company’s AMP-Rx™ product engine brings capabilities beyond conventional approaches for making protein therapeutics, opening up new territory for the products to have novel structures, enhanced biophysical properties, and more effective targeting in disease pathways. Eleven’s success is built on designing proteins ‘fit for purpose’ that are rationally designed to have ideal therapeutic characteristics and result in best-in-class biotherapeutic products for a wide range of diseases. The Cambridge, Mass.-based company was founded in 2010 by life science investors Flagship Ventures and Third Rock Ventures and world-renowned scientific experts. For more information, please visit www.elevenbio.com.
1 Topical Interleukin 1 Receptor Antagonist for Treatment of Dry Eye Disease: A Randomized Clinical Trial. JAMA Ophthalmol. April 18, 2013.